Oxford Covid-19 Vaccine

AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.

A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.

Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.

Global forecasting firm Oxford Economics on Tuesday revised India's GDP (gross domestic product) growth forecast to 7.9 per cent from earlier 7.8 per cent for the current financial year 2021-22 (FY22), citing more durable recovery and higher Covid-19 vaccination rates.

The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.

Vaccine maker Serum Institute of India (SII) has pledged 50 million pounds ($66.2 million) to the University of Oxford for setting up a research campus that would also house the institute behind the AstraZeneca-Oxford COVID-19 shot.

Two-dose COVID-19 vaccine regimens do not induce enough neutralising antibodies against the Omicron coronavirus variant, British scientists found, indicating that increased infections in those previously infected or vaccinated may be likely.

The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.

There's no evidence existing vaccines won't provide some protection against the omicron variant, the University of Oxford said as scientists scramble to assess the new Covid-19 mutation.

COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.

A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.

Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.

The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.

Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."

AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.

A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.

Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.

Global forecasting firm Oxford Economics on Tuesday revised India's GDP (gross domestic product) growth forecast to 7.9 per cent from earlier 7.8 per cent for the current financial year 2021-22 (FY22), citing more durable recovery and higher Covid-19 vaccination rates.

The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.

Vaccine maker Serum Institute of India (SII) has pledged 50 million pounds ($66.2 million) to the University of Oxford for setting up a research campus that would also house the institute behind the AstraZeneca-Oxford COVID-19 shot.

Two-dose COVID-19 vaccine regimens do not induce enough neutralising antibodies against the Omicron coronavirus variant, British scientists found, indicating that increased infections in those previously infected or vaccinated may be likely.

The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.

There's no evidence existing vaccines won't provide some protection against the omicron variant, the University of Oxford said as scientists scramble to assess the new Covid-19 mutation.

COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.

A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.

Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.

The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.

Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."